Lantheus (NASDAQ:LNTH) Sets New 1-Year High – Should You Buy?

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) hit a new 52-week high on Friday . The stock traded as high as $103.89 and last traded at $103.00, with a volume of 2009265 shares. The stock had previously closed at $94.47.

Analysts Set New Price Targets

Several brokerages have recently weighed in on LNTH. Wall Street Zen lowered shares of Lantheus from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. B. Riley Financial reiterated a “buy” rating on shares of Lantheus in a report on Friday, May 1st. JonesTrading lowered shares of Lantheus from a “buy” rating to a “hold” rating in a report on Friday, February 27th. Truist Financial reiterated a “buy” rating and set a $115.00 price objective (up from $98.00) on shares of Lantheus in a report on Monday, May 11th. Finally, Citizens Jmp increased their price objective on shares of Lantheus from $85.00 to $115.00 and gave the stock a “market outperform” rating in a report on Friday, May 8th. Eight investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $99.71.

Lantheus Price Performance

The company’s fifty day moving average is $83.21 and its 200 day moving average is $71.54. The company has a quick ratio of 2.64, a current ratio of 2.83 and a debt-to-equity ratio of 0.47. The stock has a market cap of $6.71 billion, a PE ratio of 24.82 and a beta of -0.08.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 EPS for the quarter, beating the consensus estimate of $1.25 by $0.21. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. The firm had revenue of $377.33 million for the quarter, compared to analyst estimates of $354.48 million. During the same quarter last year, the firm posted $1.53 earnings per share. Lantheus’s revenue for the quarter was up 1.2% compared to the same quarter last year. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, sell-side analysts anticipate that Lantheus Holdings, Inc. will post 4.33 earnings per share for the current fiscal year.

Institutional Trading of Lantheus

Several large investors have recently bought and sold shares of LNTH. EverSource Wealth Advisors LLC grew its position in Lantheus by 190.2% in the second quarter. EverSource Wealth Advisors LLC now owns 1,065 shares of the medical equipment provider’s stock valued at $87,000 after acquiring an additional 698 shares in the last quarter. First Trust Advisors LP grew its position in Lantheus by 37.4% in the second quarter. First Trust Advisors LP now owns 69,805 shares of the medical equipment provider’s stock valued at $5,714,000 after acquiring an additional 19,008 shares in the last quarter. Baird Financial Group Inc. grew its position in Lantheus by 22.6% in the second quarter. Baird Financial Group Inc. now owns 2,715 shares of the medical equipment provider’s stock valued at $222,000 after acquiring an additional 500 shares in the last quarter. Daiwa Securities Group Inc. grew its position in Lantheus by 88.1% in the second quarter. Daiwa Securities Group Inc. now owns 3,396 shares of the medical equipment provider’s stock valued at $278,000 after acquiring an additional 1,591 shares in the last quarter. Finally, Osterweis Capital Management Inc. acquired a new stake in Lantheus in the second quarter valued at approximately $36,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.